NCT06589440 2026-01-15Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)Stingray TherapeuticsPhase 2 Recruiting70 enrolled